Form 4: Allogene Therapeutics SVP, Finance, Annie Yoshiyama, Reports Stock Option Grant and Share Acquisition
SEC Form 4 Filing
Annie Yoshiyama, SVP of Finance at Allogene Therapeutics, acquired 36,232 shares and was granted options for 128,093 shares on January 24, 2025.
Summary
- Annie Yoshiyama, Senior Vice President of Finance at Allogene Therapeutics, reported a transaction on January 24, 2025.
- She acquired 36,232 shares of common stock at a price of $0.
- She was also granted stock options for 128,093 shares with an exercise price of $1.94.
- The stock options vest over time, with 25% vesting on January 24, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter.
- Following these transactions, Ms. Yoshiyama directly owns 137,990 shares and 128,093 stock options.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction, but the acquisition of shares and stock options by a key executive is generally viewed positively as it aligns their interests with shareholders.
Positives
- The acquisition of shares and stock options by a key executive could be seen as a positive sign of confidence in the company's future.
Future Outlook
The stock options will vest over time, with 25% vesting on January 24, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It is a routine part of corporate governance and transparency.
Comparison to Industry Standards
- Stock option grants and share acquisitions are common forms of executive compensation in the biotechnology industry.
- The vesting schedule of the stock options is typical, with a cliff vesting period followed by monthly vesting.
- The exercise price of $1.94 is a standard practice for stock options.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment, as it indicates confidence from a key executive.
Key Dates
| Date | Description |
|---|---|
| June 17, 2024 | Date of the Power of Attorney document. |
| January 24, 2025 | Date of the stock and option transaction. |
| January 24, 2026 | Date when 25% of the stock options begin to vest. |
| January 28, 2025 | Date the Form 4 was signed. |
| January 24, 2035 | Expiration date of the stock options. |
Keywords
Allogene Therapeutics, Stock Options, Share Acquisition, Form 4, Insider Trading, Annie Yoshiyama, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.